Long-lasting response of chronic lymphocytic leukemia and multiple sclerosis in a patient treated with oral fludarabine alone.
D'Arena
Giovanni
G
Gasperini
Claudio
C
Cascavilla
Nicola
N
D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists; D014740:Vidarabine; C024352:fludarabine